Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

By S. Hanauer, W. Sandborn, P. Rutgeerts, R. Fedorak, M. Lukáš, D. Macintosh, R. Panaccione, D. Wolf, P. Pollack. Gastroenterology, 2006

1,728 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Rheumatology

View Paper: https://www.semanticscholar.org/paper/dab88835fadbd410b0eb3c6ac0fc1b89d9ec5105

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. W. Sandborn
2. J. Colombel
3. S. Hanauer
4. Stefan Schreiber

In Genetics

1. W. Sandborn
2. Stefan Schreiber
3. J. Colombel
4. S. Hanauer
5. Markus F. Neurath

In Rheumatology

1. Stefan Schreiber
2. W. Sandborn
3. J. Colombel
4. D. Tracey
5. Lars Klareskog
6. J. Salfeld
7. P. Tak
8. E. Sasso

Citations in the corpus

• Guidelines for the management of inflammatory bowel disease in adults (2011, background): “ADA has demonstrated efficacy in moderate to severely active luminal Crohn's disease in both anti-TNF naive patients and in those who failed IFX therapy. In CLASSIC-I, 30% of patients treated with ADA (160/80 mg or 80/40 mg) entered clinical remission versus 12% given placebo (p=0.004).”
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial (2011, background): “dosing higher than 160/80 mg of adalimumab has not been tested. Dosing in the adalimumab induction trial in patients with ulcerative colitis was based on the doses of adalimumab known to be safe and effective in Crohn's disease.”
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “…have also been seen with etanercept in RA (Moreland et al., 1997; Catrina et al., 2002), with etanercept in spondyloartropathies (Kruithof et al., 2005) and with infliximab (Van Deventer, 1997), adalimumab (Hanauer et al., 2006) or certolizumab (Schreiber et al., 2005) in Crohn's disease.”
• Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial (2008, result): “Antibodies to infliximab, n (%)** Absent 91 (57) 88 (59) Indeterminate†† 8 (6)‡‡ 12 (8) Present 60 (38)‡‡ 50 (33) Concomitant medication, n (%) Steroids§§ 73 (44) 55 (35) Any immunosuppressive agent 85 (51) 73 (46) 5-aminosalicylates 60 (36) 45 (28) Current smoker, n (%) 56 (34) 55 (35)”